MEXATE-AQ PRESERVED Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mexate-aq Preserved, and what generic alternatives are available?
Mexate-aq Preserved is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in MEXATE-AQ PRESERVED is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mexate-aq Preserved
A generic version of MEXATE-AQ PRESERVED was approved as methotrexate sodium by HIKMA on September 16th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEXATE-AQ PRESERVED?
- What are the global sales for MEXATE-AQ PRESERVED?
- What is Average Wholesale Price for MEXATE-AQ PRESERVED?
Summary for MEXATE-AQ PRESERVED
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 40 |
Patent Applications: | 4,433 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MEXATE-AQ PRESERVED at DailyMed |
![MEXATE-AQ PRESERVED drug patent expirations Drug patent expirations by year for MEXATE-AQ PRESERVED](/p/graph/s/t/MEXATE-AQ_PRESERVED-patent-expirations.png)
US Patents and Regulatory Information for MEXATE-AQ PRESERVED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | MEXATE-AQ PRESERVED | methotrexate sodium | INJECTABLE;INJECTION | 089887-001 | Apr 14, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |